Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMI5EPB)

• Drug Name: DUP-734 Drug Info
• Synonyms: 1-(Cyclopropylmethyl)-4-[2-(4-fluorophenyl)-2-oxoethyl]piperidine hydrobromide

Indication

Disease Entry	ICD 11	Status	REF
Psychotic disorder	6A20-6A25	Discontinued in Phase 1	[1]

• Cross-matching ID:
  PubChem CID: 121967
  CAS Number: CAS 135135-87-4
  TTD Drug ID: DMI5EPB

Molecule-Related Drug Atlas

Drug(s) Targeting 5-HT 2A receptor (HTR2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[3]
ZOTEPINE	DMF3VXA	Anxiety disorder	6B00-6B0Z	Approved	[4]
Iloperidone	DM6AUFY	Schizophrenia	6A20	Approved	[5]
Flibanserin	DM70DTN	Depression	6A70-6A7Z	Approved	[6]
Lurasidone hydrochloride	DMCVPXO	Schizophrenia	6A20	Approved	[7]
Aniracetam	DMOIFW0	Cerebrovascular ischaemia	8B1Z	Approved	[8]
lumateperone tosylate	DMQ8HOJ	Schizophrenia	6A20	Approved	[9]
Sarpogrelate	DMGLP6S	Diabetic complication	5A2Y	Approved	[10]
Pimavanserin	DMR7IVC	Parkinson disease	8A00.0	Approved	[11]
Zicronapine	DMP8ESD	Schizophrenia	6A20	Phase 3	[12]

Drug(s) Targeting Opioid receptor sigma 1 (OPRS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dextromethorphan	DMUDJZM	Allergic rhinitis	CA08.0	Approved	[13]
Dextromethorphan Polistirex	DMEHCY5	Dry cough	MD12	Approved	[14]
CM-2395	DMASPWR	Schizophrenia	6A20	Phase 3	[15]
AVP-786	DMV1SOR	Alzheimer disease	8A20	Phase 3	[16]
ADX N05	DMLBYRA	Mood disorder	6A60-6E23	Phase 3	[17]
Igmesine	DMH97XA	Major depressive disorder	6A70.3	Phase 2	[18]
OPC-14523	DMB1WF3	Bulimia nervosa	6B81	Phase 2	[19]
ANAVEX 2-73	DM67OU4	Alzheimer disease	8A20	Phase 1	[20]
SSR-125047	DMSUFW6	Schizophrenia	6A20	Phase 1	[21]
SA-5845	DM6XZRL	Central nervous system disease	8A04-8D87	Phase 1	[22]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 2A receptor (HTR2A)	TTJQOD7	5HT2A_HUMAN	Modulator	[2]
Opioid receptor sigma 1 (OPRS1)	TT5TPI6	SGMR1_HUMAN	Modulator	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001777)
• [2] Piperidinyltetralin sigma ligands. J Med Chem. 1994 Feb 4;37(3):364-70.
• [3] Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
• [4] Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501.
• [5] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [6] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [7] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [8] Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
• [9] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [10] Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30.
• [11] Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52.
• [12] Clinical pipeline report, company report or official report of Lundbeck.
• [13] Dextromethorphan/quinidine: AVP 923, dextromethorphan/cytochrome P450-2D6 inhibitor, quinidine/dextromethorphan. Drugs R D. 2005;6(3):174-7.
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [15] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
• [16] Antitussives and substance abuse. Subst Abuse Rehabil. 2013 Nov 6;4:75-82.
• [17] Clinical pipeline report, company report or official report of SK BioPhamaceuticals.
• [18] Antiamnesic and neuroprotective effects of donepezil against learning impairments induced in mice by exposure to carbon monoxide gas. J Pharmacol Exp Ther. 2006 Jun;317(3):1307-19.
• [19] Antidepressant-like responses to the combined sigma and 5-HT1A receptor agonist OPC-14523. Neuropharmacology. 2001 Dec;41(8):976-88.
• [20] 2011 Pipeline of Anavex.
• [21] The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
• [22] Tumor imaging with 2 sigma-receptor ligands, 18F-FE-SA5845 and 11C-SA4503: a feasibility study. J Nucl Med. 2004 Nov;45(11):1939-45.